Gracell Biotechnologies Inc. (GRCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gracell Biotechnologies Inc. (GRCL) has a cash flow conversion efficiency ratio of -0.029x as of March 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.95 Million) by net assets ($2.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GRCL market cap overview for the company's overall valuation and market capitalisation.
Gracell Biotechnologies Inc. - Cash Flow Conversion Efficiency Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View GRCL live share price for real-time trading data and today's change.
Gracell Biotechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gracell Biotechnologies Inc. ranked by their cash flow conversion efficiency. Review financial flexibility index of Gracell Biotechnologies Inc. to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dazhong Transportation Group Co Ltd A
SHG:600611
|
0.028x |
|
Edan Instruments Inc
SHE:300206
|
0.036x |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
0.002x |
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
0.021x |
|
TWO HARBORS INV. DL-0001
F:2H2
|
0.066x |
|
Charoen Pokphand Enterprise Taiwan Co Ltd
TW:1215
|
0.048x |
|
Horizon Bancorp
NASDAQ:HBNC
|
0.046x |
|
National Presto Industries Inc
NYSE:NPK
|
0.079x |
Annual Cash Flow Conversion Efficiency for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual cash flow conversion efficiency of Gracell Biotechnologies Inc. from 2018 to 2022. Also see Gracell Biotechnologies Inc. balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $1.38 Billion | $-3.31 Billion | -2.404x | -1342.35% |
| 2021-12-31 | $1.83 Billion | $-304.55 Million | -0.167x | +31.06% |
| 2020-12-31 | $819.66 Million | $-198.15 Million | -0.242x | +54.41% |
| 2019-12-31 | $255.36 Million | $-135.39 Million | -0.530x | +97.96% |
| 2018-12-31 | $2.38 Million | $-61.86 Million | -25.957x | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more